Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a p...
Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study
About this item
Full title
Author / Creator
Publisher
New Zealand: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
Osteoporosis is a progressive bone disorder. Its medical therapy typically involves calcium, vitamin D and antiresorptive drugs. The anabolic parathyroid hormones (PTHs) represent a major advance since they stimulate new bone formation. Two forms of recombinant human PTH (rhPTH) have been evaluated: the 34-amino acid fragment rhPTH(1-34) and the in...
Alternative Titles
Full title
Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_817471503
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_817471503
Other Identifiers
ISSN
1173-2563
E-ISSN
1179-1918
DOI
10.2165/11538880-000000000-00000
